Meta-Analysis Examining Efficacy of Nicotine Partial Receptor Agonist in Tobacco Cessation (2012) [MEDLINE]
Cytisine increased the chances of quitting, although absolute quit rates were modest
Varenicline (at standard dose) increased the chances of successful long-term smoking cessation between 2-3x compared with pharmacologically-unassisted quit attempts
More participants quit successfully with varenicline than with bupropion
Limited evidence suggests that varenicline may have a role to play in relapse prevention
Systematic Review/Meta-Analysis of Cytisine in Tobacco Cessation (2013) [MEDLINE]: cytisine is an effective treatment for smoking cessation with efficacy comparable to that of other currently licensed treatments
Australian New Zealand Clinical Trials Group Open Label, Non-Inferiority Trial Comparing Cytisine to Nicotine Replacement (2014) [MEDLINE]: when combined with brief behavioral support, cytisine was superior to nicotine-replacement therapy in helping smokers quit smoking at 1 mo/2 mo/6 mo
Cytisine was associated with a higher frequency of self-reported adverse events (predominantly nausea/vomiting and sleep disorders): however, only 5% of the cytisine subjects discontinued the treatment
Many of the subjects in this study had previously tried nicotine replacement therapy, and all the participants received vouchers for lower cost nicotine replacement: in the cytisine group, 4% used the nicotine replacement vouchers
Pharmacology
Partial Agonist of α4β2 Nicotinic Acetylcholine Receptor: similar to varenicline (se xxxx, [[xxxx]])
